sumatriptan has been researched along with Neurogenic Inflammation in 4 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Neurogenic Inflammation: Inflammation caused by an injurious stimulus of peripheral neurons and resulting in release of neuropeptides which affect vascular permeability and help initiate proinflammatory and immune reactions at the site of injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examine the effect of nasal sumatriptan as an adjunctive therapy in 3 patients with idiopathic trigeminal neuralgia refractory to carbamazepine (CBZ) and found that this therapy might be suitable for patients for whom the CBZ dose cannot be increased, who are under poor pain control, and who are not candidates for nerve blocks or surgery." | 7.75 | Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases. ( Miyashita, K; Motegi, R; Shimohata, K; Shimohata, T, 2009) |
| "Sumatriptan was administered locally (20 microl, 50 or 100 nM, s." | 5.35 | Activation of the 5-HT1B/D receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin. ( Carmichael, NM; Charlton, MP; Dostrovsky, JO, 2008) |
| "We examine the effect of nasal sumatriptan as an adjunctive therapy in 3 patients with idiopathic trigeminal neuralgia refractory to carbamazepine (CBZ) and found that this therapy might be suitable for patients for whom the CBZ dose cannot be increased, who are under poor pain control, and who are not candidates for nerve blocks or surgery." | 3.75 | Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases. ( Miyashita, K; Motegi, R; Shimohata, K; Shimohata, T, 2009) |
| "We evaluated the acute antimigraine efficacy of intravenous and oral CP-122,288 in two double-blind studies." | 2.69 | No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. ( Christianssen, I; Diener, HC; Ellis, P; Ferrari, MD; Hettiarachchi, J; Kleinermans, D; Kok, JG; Olesen, J; Poole, PH; Roon, KI, 2000) |
| "Effective antimigraine agents such as ergots, triptans, opioids, and valproate inhibit preclinical neurogenic dural extravasation, suggesting that this activity may be a predictor of potential clinical efficacy of novel agents." | 2.41 | Neurogenic inflammation in the context of migraine. ( Hargreaves, RJ; Williamson, DJ, 2001) |
| "Sumatriptan was administered locally (20 microl, 50 or 100 nM, s." | 1.35 | Activation of the 5-HT1B/D receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin. ( Carmichael, NM; Charlton, MP; Dostrovsky, JO, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimohata, K | 1 |
| Shimohata, T | 1 |
| Motegi, R | 1 |
| Miyashita, K | 1 |
| Carmichael, NM | 1 |
| Charlton, MP | 1 |
| Dostrovsky, JO | 1 |
| Roon, KI | 1 |
| Olesen, J | 1 |
| Diener, HC | 1 |
| Ellis, P | 1 |
| Hettiarachchi, J | 1 |
| Poole, PH | 1 |
| Christianssen, I | 1 |
| Kleinermans, D | 1 |
| Kok, JG | 1 |
| Ferrari, MD | 1 |
| Williamson, DJ | 1 |
| Hargreaves, RJ | 1 |
1 review available for sumatriptan and Neurogenic Inflammation
| Article | Year |
|---|---|
Neurogenic inflammation in the context of migraine.
Topics: Animals; Blood Proteins; Bosentan; Calcitonin Gene-Related Peptide; Capillary Permeability; Dihydroe | 2001 |
1 trial available for sumatriptan and Neurogenic Inflammation
| Article | Year |
|---|---|
No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Huma | 2000 |
2 other studies available for sumatriptan and Neurogenic Inflammation
| Article | Year |
|---|---|
Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases.
Topics: Administration, Intranasal; Aged; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; | 2009 |
Activation of the 5-HT1B/D receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin.
Topics: Animals; Capsaicin; Hindlimb; Male; Neurogenic Inflammation; Neurons, Afferent; Rats; Rats, Sprague- | 2008 |